Practice Management

Top Story

ASCO expands enrollment for TAPUR study

ASCO expands enrollment for TAPUR study
November 17, 2017

ASCO announced four cohorts of Targeted Agent and Profiling Utilization Registry, or TAPUR, will enroll additional patients with a variety of cancers.

The combination of nivolumab (Opidvo, Bristol-Myers Squibb) plus ipilimumab (Yervoy, Bristol-Myers Squibb) also is being added to the study, bringing the number of drugs evaluated to 19, with 16 different targeted therapy options.

Meeting News

Gottlieb sees ‘watershed opportunity’ to shape future of FDA’s regulatory process

November 16, 2017
WASHINGTON — When diagnosed with Hodgkin lymphoma at…
Meeting News

AMA adopts new strategy for genetic tests, therapeutics

November 15, 2017
AMA recently voted to advance the development of a comprehensive strategy that allows more consistent coverage of genomic and genetic tests and precision medicine, a…
FDA News

FDA authorizes IMPACT test to rapidly identify cancer mutations

November 15, 2017
The FDA today authorized Integrated Mutation Profiling of Actionable Cancer Targets, or IMPACT, an in vitro diagnostic test that uses next-generation sequencing to…
More Headlines »
CME

Expert Perspectives: The Latest Evidence Regarding Immune Checkpoint Inhibitors for Advanced Bladder Cancer

This activity is supported by an educational grant from Merck & Co., Inc.

In 2016, the first immune checkpoint inhibitor was approved by the US Food and Drug Administration (FDA) for the…
More »
Video
Meeting News

VIDEO: Past AMA president discusses importance of physicians advocating for patients

September 15, 2017
More »
Resource Centers

CME

Diagnostic and Therapeutic Challenges in Von Willebrand Disease

This activity is supported by an educational grant from Shire.

With the significant variability in the subtypes and clinical manifestations of von Willebrand disease (VWD), diagnosis…
More »